Incyte said on March 25, 2026 it changed Pablo J. Cagnoni's title to President, Incyte and Global Head of Research and Development, effective immediately, with him replacing William J. Meury as President, Incyte.

1. 01

   Incyte said on March 25, 2026 it changed Pablo J. Cagnoni's title to President, Incyte and Global Head of Research and Development, effective immediately, with him replacing William J. Meury as President, Incyte.

2. 02

   The company said William J. Meury remains Chief Executive Officer and a member of the Board of Directors, and that there were no changes to compensation arrangements for the affected executives in connection with these title changes.

3. 03

   Incyte said it appointed Steven H. Stein as Executive Vice President, Chief Medical Officer and Head of Late-stage Development and Mohamed Issa as Executive Vice President and Head of U.S. Commercial, and that it is integrating U.S. Oncology and U.S. Immunology into a single U.S. commercial organization.

4. 04

   The company said in its press release that Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.